The United States Thrombotic Microangiopathy (USTMA) Consortium was formed in 2014 as a collaborative initiative to organize research efforts in the thrombotic microangiopathies (TMAs). Atypical HUS is often known as…
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question to our expert. Can a complement inhibitor be stopped…
Genetic testing again a topic but this time it is of the patient; and is important for prognosis as well as diagnosis of the patients. However some healthcare providers are…
Jump to Section: About aHUS | Special Events | Clinical Information | Networks and Support | Patient Materials & Resources |aHUS Global Advocate: NEWSLETTER |aHUS alliance Global Action | aHUS…
Algorithms to diagnose aHUS apart from other syndromes of TMA exist, but why do these tools with problem solving steps seem under-utilized?
Atypical HUS research highlights for Sept 2023 – additions to our aHUS-specific research library
Anyone who can get aHUS can get it any time. That makes sense the disease is just the product of a known or unknown genetic factor and a trigger. If…
There are two involved in a pregnancy and birth the mother and the foetus /baby. The mother may or may not have had aHUS before or during birth. Usually it…